중증근무력증 치료 시장 기회, 성장 촉진요인, 산업 동향 분석 및 예측(2025-2034년)

The Global Myasthenia Gravis Treatment Market was valued at USD 1.8 billion in 2024 and is estimated to grow at a CAGR of 7.6% to reach USD 3.8 billion by 2034. This steady growth trajectory reflects a rising global awareness of myasthenia gravis, an autoimmune neuromuscular disorder marked by weakness in the skeletal muscles. As diagnostic capabilities continue to improve across developed and emerging regions, early-stage identification of the disease is becoming more frequent. This is prompting a surge in the demand for timely and effective treatment interventions. The growing elderly population, who are more prone to autoimmune diseases due to a naturally declining immune system, is playing a key role in driving case numbers upward.

Additionally, evolving patient preferences for non-invasive, pharmaceutical-based treatments over surgical options are contributing to the rising demand for innovative therapies. Increased healthcare expenditure, favorable reimbursement policies, and government support for rare disease management are further fueling the expansion of the myasthenia gravis treatment market. The competitive landscape is also witnessing a shift as pharmaceutical companies invest more aggressively in research and development to bring advanced treatment options to market. Drug manufacturers are prioritizing targeted therapies to improve quality of life and reduce side effects, while collaborations between biotech firms and medical institutions are supporting faster innovation. These elements collectively point to a market that is poised for long-term, sustainable growth driven by both patient needs and technological progress.

The market is segmented by treatment types, including medication, therapy, and surgery. Among these, the medication segment is expected to drive the largest portion of revenue growth, with a projected CAGR of 7.7% and a market value forecast to reach USD 2.9 billion by 2034. The surge in global cases of myasthenia gravis is increasing the demand for reliable pharmaceutical treatments, including monoclonal antibodies and immunosuppressants. In parallel, therapies such as intravenous immunoglobulin (IVIG) and plasmapheresis are gaining popularity due to their clinical effectiveness in managing moderate to severe symptoms.

Based on distribution channels, the market is categorized into hospital pharmacies, retail pharmacies, and e-commerce platforms. Hospital pharmacies accounted for a significant share, with revenues reaching USD 1 billion in 2024. This growth is largely due to the rising preference for biologic therapies that require medical supervision and specialized administration. Additionally, insurance coverage for advanced biological treatments is supporting hospital-based distribution models.

The U.S. Myasthenia Gravis Treatment Market was valued at USD 733.3 million in 2024. Regulatory support from the U.S. FDA, including fast-track approvals and orphan drug designations, is encouraging the launch of new therapies. The U.S. healthcare ecosystem, backed by leading pharmaceutical firms, continues to play a crucial role in pushing forward innovation and improving patient outcomes.

Key players in the industry include Johnson & Johnson, Pfizer, Alexion Pharmaceuticals, Amgen, AbbVie, Astellas Pharma, Teva Pharmaceutical Industries, F. Hoffmann-La Roche, Mitsubishi Tanabe Pharma Corporation, UCB Pharma, Grifols, GlaxoSmithKline, Novartis, Sanofi, and Bausch Health Companies. These companies are actively expanding their treatment pipelines with a focus on monoclonal antibodies, immunosuppressants, and strategic partnerships to advance R&D and streamline market access for patients worldwide.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of myasthenia gravis
    • 3.2.1.2 Advancements in biologic therapies
    • 3.2.1.3 Growing geriatric population
    • 3.2.1.4 Favorable regulatory approvals and research funding
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of treatment
    • 3.2.2.2 Limited awareness and misdiagnosis
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technology landscape
• 3.6 Pipeline analysis
• 3.7 Future market trends
• 3.8 Gap analysis
• 3.9 Porter's analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Medication
  • 5.2.1 Cholinesterase inhibitors
  • 5.2.2 Corticosteroids
  • 5.2.3 Immunosuppressants
  • 5.2.4 Monoclonal antibodies
• 5.3 Therapy
  • 5.3.1 Intravenous immunoglobulin (IVIG)
  • 5.3.2 Plasmapheresis
• 5.4 Surgery

Chapter 6 Market Estimates and Forecast, By Disease Type, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Ocular myasthenia gravis
• 6.3 Generalized myasthenia gravis

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Hospital pharmacies
• 7.3 Retail pharmacies
• 7.4 E-commerce

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 AbbVie
• 9.2 Alexion Pharmaceuticals
• 9.3 Amgen
• 9.4 Argenx
• 9.5 Astellas Pharma
• 9.6 Bausch Health Companies
• 9.7 F. Hoffmann-La Roche
• 9.8 GlaxoSmithKline
• 9.9 Grifols
• 9.10 Mitsubishi Tanabe Pharma Corporation
• 9.11 Novartis
• 9.12 Pfizer
• 9.13 Sanofi
• 9.14 Teva Pharmaceutical Industries
• 9.15 UCB Pharma